---
title: "Sanofi launches insulin in the U.S. with a \"Pay $35 per month\" plan"
description: "Sanofi US announced on September 26 that its \"Insulin Savings Program\" will significantly expand its coverage, allowing any U.S. patient with a valid prescription to purchase a 30-day supply of any Sa"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/259065222.md"
published_at: "2025-09-26T12:14:10.000Z"
---

# Sanofi launches insulin in the U.S. with a "Pay $35 per month" plan

> Sanofi US announced on September 26 that its "Insulin Savings Program" will significantly expand its coverage, allowing any U.S. patient with a valid prescription to purchase a 30-day supply of any Sanofi insulin for $35. The program was initially established for the uninsured and will now be open to all Americans, regardless of their insurance status—including those with commercial insurance or Medicare. The expanded "Insulin Savings Program" now ensures that each U.S. patient pays no more than $35 per month for Sanofi insulin

Sanofi US announced on September 26 that its "Insulin Savings Program" will significantly expand its coverage. Any U.S. patient with a valid prescription can purchase a 30-day supply of any Sanofi insulin for $35. The program was initially established for the uninsured, but it will now be open to all Americans, regardless of their insurance status—including those with commercial insurance or Medicare. The expanded "Insulin Savings Program" now ensures that each U.S. patient pays no more than $35 per month for Sanofi insulin

### Related Stocks

- [SNYNF.US - Sanofi](https://longbridge.com/en/quote/SNYNF.US.md)
- [SNY.US - Sanofi](https://longbridge.com/en/quote/SNY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 德克萨斯州起诉赛诺菲，指控其涉嫌通过'贿赂'医疗服务提供者来增加药品处方量 | 德克萨斯州检察长肯·帕克斯顿已对赛诺菲提起诉讼，指控该公司贿赂医疗服务提供者以推广其药物。诉讼称，赛诺菲的项目违反了德克萨斯州医疗保健计划欺诈预防法。帕克斯顿寻求超过一百万美元的经济赔偿和对进一步非法行为的禁令。这是继对赛诺菲及其他公司因类 | [Link](https://longbridge.com/en/news/276391061.md) |
| 赛诺菲：Beyfortus 研究表明对婴儿在首个 RSV 季节之后仍然有益 | 赛诺菲宣布，其使用 Beyfortus 的 RSV 免疫计划研究显示，在婴儿的第二个 RSV 季节中，RSV 相关住院人数显著减少。发表在《柳叶刀传染病》上的研究结果表明，该免疫计划不仅在第一个季节减少了住院和门诊疾病，还对第二个季节产生了 | [Link](https://longbridge.com/en/news/276038221.md) |
| 曼恩凯德（MNKD）估值检查：随着 Afrezza 儿童里程碑的达成，无针胰岛素的机会正在开启 | MannKind (MNKD) 已在 INHALE-1ST Afrezza 研究中招募了首位儿童患者，这可能导致首款无针胰岛素的问世。该公司的股价在过去 30 天内上涨了 8.64%，在过去 90 天内上涨了 13.20%，当前价格为 5. | [Link](https://longbridge.com/en/news/276150484.md) |
| 恢复监察长系统的责任机制 | 特朗普政府的改革呼吁联邦机构的问责制，特别是对联邦监察长委员会（CIGIE）。该委员会变得更加政治化，独立性降低，权力扩大，使其能够调查公众并使用执法权。批评者认为，CIGIE 的行为，包括剥夺正当程序保护和针对监察长，削弱了其原本的目的。 | [Link](https://longbridge.com/en/news/276257151.md) |
| 联邦农业抵押公司的盈利潜力一瞥 | 联邦农业（NYSE:AGM）定于 2026 年 2 月 19 日公布季度财报，分析师预计每股收益（EPS）为 4.51 美元。该公司此前超出 EPS 预期 0.07 美元，导致股价上涨 4.67%。目前，股票交易价格为 175.0 美元，过 | [Link](https://longbridge.com/en/news/276258598.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
